U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07637526) titled 'Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma' on May 27.
Brief Summary: The goal of this retrospective observational study is to characterize multiple myeloma (MM) patients (by collecting demographics, disease characteristics and treatment history data) treated in first or second relapse with belantamab mafodotin combinations under compassionate use conditions.
The main question it aims to answer is which belantamab combinations (belantamab mafodotin+bortezomib+dexamethasone [BVd] vs. belantamab mafodotin+pomalidomide+dexamethasone [BPd]) show higher response rates in patients...